Antidepressant response and fluvoxamine plasma concentrations: A pilot study

Pharmacy World and Science

Volumn 25, Issue 1, 2003, Pages 27-29

  Schwarzenbach, Florence ^a   Netillard, Christian ^a   Demoly, Patricia ^a   Bisschop, Dorothé ^a   Limat, Samuel ^b   Bouquet, Serge ^c   Vandel, Sylvette ^d   Bel, Anne Marie ^a   Woronoff Lemsi, Marie Christine ^b  

^a Psychiatric Hospital   (France)

^b University Hospital   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Antidepressant; Fluvoxamine; Plasma concentration; Therapeutic drug monitoring

Indexed keywords

FLUVOXAMINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; PILOT STUDY; SIDE EFFECT;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUVOXAMINE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 0347926532     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022410306577     Document Type: Article

References (10)

1. Vozeh S. Cost-effectiveness of therapeutic drug monitoring. Clin Pharmacokinet 1987; 13: 131-40.
2. Schweitzer C, Spahn H, Mutschler E. Fluorimetric determination of fluvoxamine or clovoxamine in human plasma after thin-layer chromatographic or high-performance liquid chromatographic separation. J Chromatogr 1986; 382: 405-11.
3. Sandmann J, Lörch B, Bandelow B, Härtter S, Winter P, Hiemke C et al. Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine. Pharmacopsychiatry 1998; 31(4): 117-21.
4. Spigest O, Granberg K, Hägg S, Söderström E, Dahlqvist R. Non-linear fluvoxamine disposition. Br J Clin Pharmacol 1998; 45(3): 257-63.
5. Brasseur R, Van Moffaert M, Mesotten F, Ansseau M, Uytdenhoef P, Bartholome F. A Belgian multicentre study of fluvoxamine in depressive outpatients. Acta Psychiatr Belg 1985; 85(5): 636-43.
6. Lapierre YD, Browne M, Horn E, Oyewumi LK, Sarantidis D, Roberts N et al. Treatment of major affective disorder with fluvoxamine. J Clin Psychiatry 1987; 48(2): 65-8.
7. Kasper S, Dötsch M, Kick H, Vieira A, Müller HJ. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 1993; 3: 13-21.
8. De Wilde JEM, Doogan DP. Fluvoxamine and clomipramine in endogenous depression. J Affect Disord 1982; 4: 249-59 (Abstract).
9. Devane CL, Gill HS. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. J Clin Psychiatry 1997; 58(5 Suppl): 7-14.
10. Kasper S, Dötsch M, Vieira A. Plasma levels of fluvoxamine and maprotiline and clinical response in major depression. Pharmacopsychiatry 1992; 25: 106.